Tamtam Try Tamtam free
Tandem Diabetes Care logo

Tandem Diabetes Care account plan

Manufactures insulin delivery systems

At a glance

Tandem Diabetes Care makes automated insulin delivery pumps (t:slim X2, Tandem Mobi); FY2025 sales $1,014.7 million, about 2,500 employees.

Tandem Diabetes Care (Nasdaq: TNDM) is a San Diego company that designs and sells automated insulin delivery (AID) systems: the t:slim X2 and Tandem Mobi pumps running Control-IQ+, plus single-use cartridges and infusion sets. It serves nearly 500,000 people with diabetes in more than 25 countries, selling directly in the U.S. and Canada and mostly through distributors elsewhere. FY2025 sales were $1,014.7 million (FY2024: $940.2 million), with a gross margin of 54% and a net loss of $204.7 million. It had about 2,500 regular full-time employees at end-2025, with headquarters, R&D and pump assembly in San Diego.

Business units

Strategic priorities

Reshaping the business model: pay-as-you-go pharmacy
Since Q1 2026 U.S. pharmacy contracts use pay-as-you-go, with no upfront pump reimbursement and a price premium on supplies. Pharmacy reached 15% of U.S. sales in Q3 2026 with about 50% formulary coverage, and management expects "almost all pharmacy as opposed to DME" by end of 2028.
Going direct internationally
Direct sales, training and support started in 2026 in the UK, Austria and Switzerland, with France launching; Tandem aims to serve "approximately half of our installed base by the end of next year".
Mobi tubeless launch
A 510(k) for Mobi tubeless, "the world's first and only tubeless AID system" with up to seven days of wear, was submitted in Q2 2026; clearance is expected in Q4 and full commercial availability in the first half of 2027.
Fully closed loop system
With the University of Virginia, Tandem is developing a system that needs no meal announcements; a pivotal study of more than 300 people starts in Q4 2026, with the product expected on the market in 2028.
Modernizing the commercial organization
A new CRM system was deployed in 2026 "to improve sales force efficiency and effectiveness" and support the pharmacy transition and international direct launches.
Type 2 expansion
Control-IQ+ was cleared in March 2025 for type 2 diabetes ages 18+, adding about 2.5 million U.S. people with type 2 diabetes who require intensive insulin therapy to the addressable market.

Latest results

In Q3 2026 (quarter to 30 September 2026) sales rose 14% to $283.7 million: U.S. $191.0 million (+9%) and international $92.6 million (+26%). Gross margin rose to 57% from 54% on pharmacy and direct pricing, the operating loss narrowed to $2.4 million from $22.9 million, and adjusted EBITDA was $18.0 million, or 6% of sales. About 33,000 pumps shipped worldwide. Tandem reaffirmed 2026 guidance of about $1.065 billion to $1.085 billion of sales, a 56% to 57% gross margin and a 5% to 6% adjusted EBITDA margin; for 2027 the CFO said a "mid to high single digit increase year over year is probably a really fair starting point".

Investments and deals

AMF Medical (Sigi Patch Pump)
An amended agreement in January 2025 replaced contingent earnouts with CHF 68.0 million ($75.2 million), booked as acquired IPR&D; Sigi technology underpins the next-generation Mobi patch pump.
CeQur stake
An additional CHF 64.0 million ($81.4 million) investment in CeQur SA on 22 May 2026, keeping ownership below 50%; carrying value $125.5 million.
Roche cross-licence
The May 2025 settlement and cross-licence costs $36.0 million over four years for 10-year cross-licences.
Convertible notes
$300.0 million of 0.00% convertible notes due 2032 issued in February 2026, alongside $316.3 million of 1.50% notes due 2029; cash and short-term investments were $443.1 million at 30 September 2026.

Challenges and risks

Infusion set supply constraint
A key infusion set supplier's shortages hit supply sales, with constraints expected to persist through early 2027; all currently marketed infusion sets come from Unomedical, a ConvaTec subsidiary.
Slower pharmacy adoption
Management said "the pace of transition is more gradual than we initially anticipated", and pay-as-you-go initially reduces sales and gross profit on pump shipments.
Continued losses
The FY2025 net loss was $204.7 million and the accumulated deficit $1.3 billion; profitability depends on sales growth, cost reduction and launches.
Competition and CGM partner dependence
Tandem competes with Beta Bionics, Insulet, Medtronic, mylife (formerly Ypsomed) and Sequel, and relies on CGM integration agreements with Dexcom and Abbott.
CEO transition
John Sheridan retires at the end of 2026; Jeanette Bankas joined as president and CEO on November 16.

What leadership says

“Tandem's third-quarter performance demonstrates that our strategy is delivering results”

John Sheridan, President and CEO · Q3 2026 earnings press release, 5 November 2026

“this is going to be a game changer for the business.”

John Sheridan, President and CEO · On the fully closed loop system, Q3 2026 earnings call, 5 November 2026

“reshaping our business model, modernizing our commercial organization, and delivering new technology”

John Sheridan, President and CEO · The three 2026 priorities, Q2 2026 earnings call, 6 August 2026

“mid to high single digit increase year over year is probably a really fair starting point”

Leigh Vosseller, EVP, CFO and Treasurer · On 2027 expectations, Q3 2026 earnings call, 5 November 2026

Where a supplier can help

Pharmacy channel operations
The pay-as-you-go pharmacy priority, and adoption that is more gradual than expected, point to needs in prescription workflows, payer and PBM contracting support, and patient onboarding.
Direct operations in Europe
Going direct in the UK, Switzerland, Austria and France means Tandem now handles reimbursement, tenders and fulfilment itself, creating demand for logistics, customer support and local market-access partners.
Infusion set supply resilience
The infusion set supply constraint and single-supplier dependence make second-source manufacturing, supply chain planning and contract manufacturing relevant, as does the planned launch of its own SteadySet.
Sales force tooling
The commercial modernization priority and new CRM system open room for sales enablement, CRM integration and analytics vendors supporting U.S. and international sales teams.
Clinical and launch support
The Mobi tubeless launch and the fully closed loop pivotal study of more than 300 people call for clinical research, regulatory and manufacturing scale-up services.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Tandem Diabetes Care?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Tandem Diabetes Care

What does Tandem Diabetes Care do?

Tandem designs and sells automated insulin delivery systems, the t:slim X2 and Tandem Mobi pumps running Control-IQ+, plus the cartridges and infusion sets they use. It serves nearly 500,000 people with diabetes in more than 25 countries.

What is Tandem Diabetes Care's revenue?

FY2025 sales were $1,014.7 million. Q3 2026 sales were $283.7 million (+14%), and 2026 guidance is about $1.065 billion to $1.085 billion.

How many employees does Tandem Diabetes Care have?

About 2,500 regular full-time employees at 31 December 2025, mainly in the United States, Canada and Europe.

Who leads Tandem Diabetes Care?

Jeanette Bankas joined as president and CEO on November 16, succeeding John Sheridan, who retires at the end of 2026. Leigh Vosseller is CFO and Becky Robertson chairs the Board.

What is Tandem Diabetes Care's strategy?

Tandem aims to grow through U.S. pay-as-you-go pharmacy reimbursement, direct international operations, and new technology such as Mobi tubeless and a fully closed loop system.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)